Overview

A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Status:
Terminated

Trial end date:
2011-05-23

Target enrollment:

Participant gender:

Summary

This is a Phase II, single institution, single-arm, open-label study of oral dasatinib monotherapy administered to subjects with relapsed or refractory aggressive DLBCL. This study will be conducted in two phases: a Treatment Phase and a Follow-up Phase. Research Hypothesis: Dasatinib, when administered orally at a continuous dose of 100 mg once daily, will be safe and effective in treating subjects that have failed prior therapies to diffuse large B cell lymphoma (DLBCL) or have relapsed disease.

Phase:

Phase 2

Details

Lead Sponsor:

Weill Medical College of Cornell University

Collaborator:

Bristol-Myers Squibb

Treatments:

Dasatinib